Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.
复制标题
DOI：
10.1136/jitc-2020-001403
复制
发表时间：
2020-10
影响因子：
10.9
通讯作者：
Ficorella C
中科院分区：
文献类型：
--
作者：
Cortellini A;Ricciuti B;Tiseo M;Bria E;Banna GL;Aerts JG;Barbieri F;Giusti R;Cortinovis DL;Migliorino MR;Catino A;Passiglia F;Torniai M;Morabito A;Genova C;Mazzoni F;Di Noia V;Signorelli D;Gelibter A;Occhipinti MA;Rastelli F;Chiari R;Rocco D;Inno A;De Tursi M;Di Marino P;Mansueto G;Zoratto F;Grossi F;Filetti M;Pizzutilo P;Russano M;Citarella F;Cantini L;Targato G;Nigro O;Ferrara MG;Buti S;Scodes S;Landi L;Guaitoli G;Della Gravara L;Tabbò F;Ricciardi S;De Toma A;Friedlaender A;Petrelli F;Addeo A;Porzio G;Ficorella C
肥胖与接受程序性死亡 1/程序性死亡配体 1 (PD-L1) 检查点抑制剂的患者的结局之间的关联已在预先治疗的非小细胞肺癌 (NSCLC) 患者中得到证实，无论 PD-L1 肿瘤表达如何。我们根据一大群 PD-L1 表达≥50%、接受一线派姆单抗的转移性 NSCLC 患者的基线体重指数 (BMI) 和 BMI 变化进行结果分析。我们还评估了接受一线铂类化疗的转移性非小细胞肺癌患者的对照队列。设定正常体重作为对照组。派姆单抗队列和化疗队列分别包括 962 名患者和 426 名患者。肥胖患者在派姆单抗队列中的客观缓解率 (ORR) (OR=1.61 (95% CI: 1.04–2.50)) 显着较高，而超重患者在化疗队列中的 ORR 显着较低 (OR=0.59 (95% CI: 0.37–0.92))。在派姆单抗队列中，肥胖患者的无进展生存期 (PFS) (HR=0.61 (95% CI: 0.45–0.82)) 显着延长。相反，化疗队列中他们的 PFS 显着缩短（HR=1.27（95% CI：1.01-1.60））。肥胖患者在派姆单抗队列中的总生存期 (OS) 显着延长（HR=0.70（95% CI：0.49-0.99）），而化疗队列中根据基线 BMI 没有发现显着差异。 BMI 变化显着影响派姆单抗和化疗队列的 ORR、PFS 和 OS。对于接受一线派姆单抗治疗的 PD-L1 表达≥50% 的转移性 NSCLC 患者，基线肥胖与 ORR、PFS 和 OS 显着改善相关，但在接受化疗的患者中则不然。 BMI 变化也与临床结果显着相关。
The association between obesity and outcomes in patients receiving programmed death-1/programmed death ligand-1 (PD-L1) checkpoint inhibitors has already been confirmed in pre-treated non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 tumor expression. We present the outcomes analysis according to baseline body mass index (BMI) and BMI variation in a large cohort of metastatic NSCLC patients with a PD-L1 expression ≥50%, receiving first line pembrolizumab. We also evaluated a control cohort of metastatic NSCLC patients treated with first line platinum-based chemotherapy. Normal weight was set as control group. 962 patients and 426 patients were included in the pembrolizumab and chemotherapy cohorts, respectively. Obese patients had a significantly higher objective response rate (ORR) (OR=1.61 (95% CI: 1.04–2.50)) in the pembrolizumab cohort, while overweight patients had a significantly lower ORR (OR=0.59 (95% CI: 0.37–0.92)) within the chemotherapy cohort. Obese patients had a significantly longer progression-free survival (PFS) (HR=0.61 (95% CI: 0.45–0.82)) in the pembrolizumab cohort. Conversely, they had a significantly shorter PFS in the chemotherapy cohort (HR=1.27 (95% CI: 1.01–1.60)). Obese patients had a significantly longer overall survival (OS) within the pembrolizumab cohort (HR=0.70 (95% CI: 0.49–0.99)), while no significant differences according to baseline BMI were found in the chemotherapy cohort. BMI variation significantly affected ORR, PFS and OS in both the pembrolizumab and the chemotherapy cohorts. Baseline obesity is associated to significantly improved ORR, PFS and OS in metastatic NSCLC patients with a PD-L1 expression of ≥50%, receiving first line pembrolizumab, but not among patients treated with chemotherapy. BMI variation is also significantly related to clinical outcomes.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
DOI：
10.1016/s1470-2045(18)30078-0
发表时间：
2018-03
期刊：
The Lancet. Oncology
影响因子：
--
作者：
McQuade JL;Daniel CR;Hess KR;Mak C;Wang DY;Rai RR;Park JJ;Haydu LE;Spencer C;Wongchenko M;Lane S;Lee DY;Kaper M;McKean M;Beckermann KE;Rubinstein SM;Rooney I;Musib L;Budha N;Hsu J;Nowicki TS;Avila A;Haas T;Puligandla M;Lee S;Fang S;Wargo JA;Gershenwald JE;Lee JE;Hwu P;Chapman PB;Sosman JA;Schadendorf D;Grob JJ;Flaherty KT;Walker D;Yan Y;McKenna E;Legos JJ;Carlino MS;Ribas A;Kirkwood JM;Long GV;Johnson DB;Menzies AM;Davies MA
通讯作者：
Davies MA
影响因子：
11.5
作者：
De Giorgi, Ugo;Procopio, Giuseppe;Sternberg, Cora N.
通讯作者：
Sternberg, Cora N.
影响因子：
50.5
作者：
Patel, J. D.;Pereira, J. R.;Bonomi, P. D.
通讯作者：
Bonomi, P. D.
影响因子：
7.8
作者：
Mullen M;Gonzalez-Perez RR
通讯作者：
Gonzalez-Perez RR